Hemolytic Uremic Syndrome Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: May 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, Disease Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hemolytic uremic syndrome treatment market is expected to register a revenue CAGR of 4.6% during the forecast period from 2023 to 2031.
Hemolytic Uremic Syndrome Treatment Market Fundamentals
Hemolytic uremic syndrome is a medical disorder that causes tiny blood vessels in the kidneys to get blocked. The obstruction damages your red blood cells (hemolytic anemia) and decreases your platelet count (thrombocytopenia), which are clotting cells. The kidneys are the most usually affected organs by hemolytic uremic syndrome. Shiga toxin-producing Escherichia coli is frequently the cause of diarrhea-associated hemolytic uremic syndrome. Other infections, certain drugs, or situations such as pregnancy, cancer, or autoimmune illness can also cause hemolytic uremic syndrome. In certain situations, hemolytic uremic syndrome is caused by genetic mutations. These types of hemolytic uremic syndrome rarely cause diarrhea. Most hemolytic uremic syndrome cases in children are diarrhea-related (D+ HUS). The growing case of hemolytic uremic syndrome is one of the major trends in the global market. According to the 2023 article by Food Safety News, 128 cases of hemolytic uremic syndrome were recorded in 2021 in France.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth hemolytic uremic syndrome treatment market forecasts to the industry stakeholders.
Hemolytic Uremic Syndrome Treatment Market Dynamics
The development of new medical technologies, such as dialysis machines and plasma exchange systems, has greatly improved the treatment options available for hemolytic uremic syndrome patients. As more information becomes available about hemolytic uremic syndrome and its causes, the condition becomes more recognized and diagnosed frequently. This increased awareness is likely to drive demand for hemolytic uremic syndrome treatments. Additionally, increasing cases of hemolytic uremic syndrome is also a major trend in the global market. For instance, according to a 2023 article by Food Safety News, in Europe, in 2021, 365 HUS cases were reported, with four fatalities in children. Most children ranged in age from 0 to 4 and 5 to 14 years old. With more attention being paid to rare diseases and the need for effective treatments, there is a growing trend toward research and development in the hemolytic uremic syndrome treatment market. This trend is likely to lead to the development of new therapies and treatment options for hemolytic uremic syndrome patients. Personalized medicine is an emerging trend in healthcare, and it is likely to play an increasingly important role in treating the hemolytic uremic syndrome treatment market. As more is understood about the genetic and environmental factors contributing to hemolytic uremic syndrome, personalized treatment plans tailored to individual patients will likely become more common. Regulatory agencies such as the FDA increasingly recognize the importance of developing treatments for rare diseases like hemolytic uremic syndrome. This trend will likely lead to increased funding and support for research and development in this area.
Hemolytic Uremic Syndrome Treatment Market Ecosystem
Hemolytic Uremic Syndrome Treatment Market, by Treatment Type
Hemolytic Uremic Syndrome Treatment Market, by Disease Type
Hemolytic Uremic Syndrome Treatment Market by Treatment Type
[75674]
Pharmacological therapy accounts for a notable revenue share in the global market. This segment is further bifurcated into Eculizumab and Ravulizumab. Eculizumab treats uncommon blood disorders, atypical hemolytic uremic syndrome, and paroxysmal nocturnal hemoglobinuria. It prevents red blood cells from breaking down and clumping together to create a clot. It also treats neuromyelitis optica spectrum condition and myasthenia gravis. Ravulizumab is used to treat blood diseases that produce low amounts of red blood cells (anemia) and blood clots, such as atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). It works by calming down an overactive immune system, which lowers the destruction of red blood cells. It also stops blood cells (platelets) from clotting. It may also treat myasthenia gravis, which causes muscles to quickly weaken or fatigue. It is a monoclonal antibody.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as treatment type and disease type. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps identify potential hemolytic uremic syndrome treatment market growth opportunities.
Hemolytic Uremic Syndrome Treatment Market by Region
North America has a relatively high incidence of hemolytic uremic syndrome, particularly in the United States. This high incidence drives demand for hemolytic uremic syndrome treatments, making North America a key market for these products. North America has some of the world's most advanced healthcare infrastructure and facilities. This allows for developing and deploying new treatments and technologies for hemolytic uremic syndrome. The regulatory framework for healthcare products in North America is robust, with agencies such as the FDA providing oversight and approval for new treatments. This framework provides a high level of confidence for healthcare providers and patients in the safety and efficacy of hemolytic uremic syndrome treatments. North America spends a significant amount on healthcare, with a large proportion of this spending going towards developing and deploying new treatments and technologies for rare diseases such as hemolytic uremic syndrome. North America is home to several key players in the hemolytic uremic syndrome treatment market, including pharmaceutical companies, biotechnology companies, and medical device manufacturers. The presence of these companies contributes to the growth and development of the market in the region.
Based on the regions, the global hemolytic uremic syndrome treatment market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding the hemolytic uremic syndrome treatment market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
Hemolytic Uremic Syndrome Treatment Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the industry trends.
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney damage characterize hemolytic uremic syndrome (HUS). Major hemolytic uremic syndrome cases occur among children and are caused by Shiga toxin-producing Escherichia coli (STEC).
North America accounts for the largest revenue share in the global hemolytic uremic syndrome treatment therapy market
The global hemolytic uremic syndrome treatment market is estimated to grow at a revenue CAGR of 4.6% from 2023 to 2031
Growing R&D activities to create novel therapies are some of the prominent trends in global hemolytic uremic syndrome treatment.
The high cost of the therapy and safety concerns are the major restraining factor that can hamper the overall market growth.
Novartis AG, Hoffmann-La Roche Ltd., Tasly Biopharmaceuticals Co. Ltd., and other notable players are some of the major market players in the global hemolytic uremic syndrome treatment market.
The atypical hemorrhagic colitis and hemolytic uremic syndrome segment accounts for the highest revenue share in the global market
Pharmacological therapy segment accounts for the highest revenue share in the global market
*Insights on financial performance are subject to the availability of information in the public domain